Selective Cox-2 Inhibitors Industry: Global Market Status and Forecast 2021-2027
Report Code: KNJ1002724
Publisher: Date of Publish:
No. of Pages: 140 Category: Pharmaceuticals and Healthcare Publisher: Date of Publish:
This report provides a comprehensive analysis of current global Selective Cox-2 Inhibitors market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Selective Cox-2 Inhibitors industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies. According to this survey, the global Selective Cox-2 Inhibitors market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027. Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Selective Cox-2 Inhibitors Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Selective Cox-2 Inhibitors market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. The Global Selective Cox-2 Inhibitors Market has been exhibited in detail in the following chapters Chapter 1 displays the basic product introduction and market overview. Chapter 2 provides the competition landscape of global Selective Cox-2 Inhibitors industry. Chapter 3 provides the market analysis by type and by region Chapter 4 provides the market analysis by application and by region Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis. Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. Chapter 12 provides the market forecast by type and by application Chapter 13 provides the market forecast by region Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis. Chapter 15 conclusions Segmented by Type Meloxicam Celecoxib Etoricoxib Imrecoxib Etodolac Parecoxib Other Segmented by Application Rheumatoid Arthritis Osteoarthritis Spondylosis Chronica Ankylopoietica Other Segmented by Country North America United States Canada Mexico Europe Germany France UK Italy Russia Spain Asia Pacific China Japan Korea Southeast Asia India Australasia Central & South America Brazil Argentina Colombia Middle East & Africa Iran Israel Turkey South Africa Saudi Arabia Key manufacturers included in this survey Yung Shin Pharmaceutical Teva TerSera Therapeutics Taro Pharmaceuticals Takeda Qilu Pharmaceutical PuraCap Pharmaceutical Pfizer Perrigo Novacap Mylan Merck Meda Pharmaceuticals Lupin Pharmaceuticals Kopran Kelun Group Iroko Pharmaceuticals Hengrui pharmaceutical Glenmark Pharmaceuticals Geri-Care Cipla Breckenridge Pharmaceutical Boehringer-Ingelheim Bayer Aurobindo Pharma Apotex Almirall Limited Abbott
Table of Contents 1 Product Introduction and Overview 1.1 Product Definition 1.2 Product Specification 1.3 Global Market Overview 1.3.1 Global Selective Cox-2 Inhibitors Market Status and Forecast (2016-2027) 1.3.2 Global Selective Cox-2 Inhibitors Sales Value CAGR by Region 1.4 Market Drivers, Inhibitors 1.4.1 Market Drivers 1.4.2 Market Inhibitors 1.4.3 COVID-19 Impact Analysis 2 Global Selective Cox-2 Inhibitors Supply by Company 2.1 Global Selective Cox-2 Inhibitors Sales Value by Company 2.2 Selective Cox-2 Inhibitors Sales Area of Main Manufacturers 2.3 Trend of Concentration Rate 3 Global and Regional Selective Cox-2 Inhibitors Market Status by Type 3.1 Selective Cox-2 Inhibitors Type Introduction 3.1.1 Meloxicam 3.1.2 Celecoxib 3.1.3 Etoricoxib 3.1.4 Imrecoxib 3.1.5 Etodolac 3.1.6 Parecoxib 3.1.7 Other 3.2 Global Selective Cox-2 Inhibitors Market by Type 3.3 North America: by Type 3.4 Europe: by Type 3.5 Asia Pacific: by Type 3.6 Central & South America: by Type 3.7 Middle East & Africa: by Type 4 Global and Regional Selective Cox-2 Inhibitors Market Status by Application 4.1 Selective Cox-2 Inhibitors Segment by Application 4.1.1 Rheumatoid Arthritis 4.1.2 Osteoarthritis 4.1.3 Spondylosis Chronica Ankylopoietica 4.1.4 Other 4.2 Global Selective Cox-2 Inhibitors Market by Application 4.3 North America: by Application 4.4 Europe: by Application 4.5 Asia Pacific: by Application 4.6 Central & South America: by Application 4.7 Middle East & Africa: by Application 5 Global Selective Cox-2 Inhibitors Market Status by Region 5.1 Global Selective Cox-2 Inhibitors Market by Region 5.2 North America Selective Cox-2 Inhibitors Market Status 5.3 Europe Selective Cox-2 Inhibitors Market Status 5.4 Asia Pacific Selective Cox-2 Inhibitors Market Status 5.5 Central & South America Selective Cox-2 Inhibitors Market Status 5.6 Middle East & Africa Selective Cox-2 Inhibitors Market Status 6 North America Selective Cox-2 Inhibitors Market Status 6.1 North America Selective Cox-2 Inhibitors Market by Country 6.2 United States 6.3 Canada 6.4 Mexico 7 Europe Selective Cox-2 Inhibitors Market Status 7.1 Europe Selective Cox-2 Inhibitors Market by Country 7.2 Germany 7.3 France 7.4 UK 7.5 Italy 7.6 Russia 7.7 Spain 8 Asia Pacific Selective Cox-2 Inhibitors Market Status 8.1 Asia Pacific Selective Cox-2 Inhibitors Market by Country 8.2 China 8.3 Japan 8.4 Korea 8.5 Southeast Asia 8.6 India 8.7 Australasia 9 Central & South America Selective Cox-2 Inhibitors Market Status 9.1 Central & South America Selective Cox-2 Inhibitors Market by Country 9.2 Brazil 9.3 Argentina 9.4 Colombia 10 Middle East & Africa Selective Cox-2 Inhibitors Market Status 10.1 Middle East & Africa Selective Cox-2 Inhibitors Market by Country 10.2 Iran 10.3 Israel 10.4 Turkey 10.5 South Africa 10.8 Saudi Arabia 11 Major Downstream Customers Analysis 11.1 Customer One Analysis 11.2 Customer Two Analysis 11.3 Customer Three Analysis 11.4 Customer Four Analysis 12 Global Selective Cox-2 Inhibitors Market Forecast by Type and by Application 12.1 Global Selective Cox-2 Inhibitors Sales Value Forecast (2022-2027) 12.2 Global Selective Cox-2 Inhibitors Forecast by Type 12.3 Global Selective Cox-2 Inhibitors Forecast by Application 13 Global Selective Cox-2 Inhibitors Market Forecast by Region/Country 13.1 Global Selective Cox-2 Inhibitors Market Forecast by Region (2022-2027) 13.2 North America Market Forecast 13.3 Europe Market Forecast 13.4 Asia Pacific Market Forecast 13.5 Central & South America Market Forecast 13.6 Middle East & Africa Market Forecast 14 Key Participants Company Information 14.1 Yung Shin Pharmaceutical 14.1.1 Company Information 14.1.2 Selective Cox-2 Inhibitors Product Introduction 14.1.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.1.4 SWOT Analysis 14.2 Teva 14.2.1 Company Information 14.2.2 Selective Cox-2 Inhibitors Product Introduction 14.2.3 Teva Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.2.4 SWOT Analysis 14.3 TerSera Therapeutics 14.3.1 Company Information 14.3.2 Selective Cox-2 Inhibitors Product Introduction 14.3.3 TerSera Therapeutics Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.3.4 SWOT Analysis 14.4 Taro Pharmaceuticals 14.4.1 Company Information 14.4.2 Selective Cox-2 Inhibitors Product Introduction 14.4.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.4.4 SWOT Analysis 14.5 Takeda 14.5.1 Company Information 14.5.2 Selective Cox-2 Inhibitors Product Introduction 14.5.3 Takeda Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.5.4 SWOT Analysis 14.6 Qilu Pharmaceutical 14.6.1 Company Information 14.6.2 Selective Cox-2 Inhibitors Product Introduction 14.6.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.6.4 SWOT Analysis 14.7 PuraCap Pharmaceutical 14.7.1 Company Information 14.7.2 Selective Cox-2 Inhibitors Product Introduction 14.7.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.7.4 SWOT Analysis 14.8 Pfizer 14.8.1 Company Information 14.8.2 Selective Cox-2 Inhibitors Product Introduction 14.8.3 Pfizer Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.8.4 SWOT Analysis 14.9 Perrigo 14.9.1 Company Information 14.9.2 Selective Cox-2 Inhibitors Product Introduction 14.9.3 Perrigo Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.9.4 SWOT Analysis 14.10 Novacap 14.10.1 Company Information 14.10.2 Selective Cox-2 Inhibitors Product Introduction 14.10.3 Novacap Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021) 14.10.4 SWOT Analysis 14.11 Mylan 14.12 Merck 14.13 Meda Pharmaceuticals 14.14 Lupin Pharmaceuticals 14.15 Kopran 14.16 Kelun Group 14.17 Iroko Pharmaceuticals 14.18 Hengrui pharmaceutical 14.19 Glenmark Pharmaceuticals 14.20 Geri-Care 14.21 Cipla 14.22 Breckenridge Pharmaceutical 14.23 Boehringer-Ingelheim 14.24 Bayer 14.25 Aurobindo Pharma 14.26 Apotex 14.27 Almirall Limited 14.28 Abbott 15 Conclusion 16 Methodology
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com